Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY 4.0JAMA Network Open

Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths

  • Scott E. Hadland1,2
  • Ijeoma Opara3
  • Vicki Fung2,4
  • Dandi Dong1
  • Sitara Weerakoon3
  • Jonathan Rodean5
  • Marie-Abèle C. Bind2,6
  • Bonnie T. Zima7
  • Meredith Glass1
  • Margarita Alegría2,8
  • George Karandinos2,9
  • Arthur Robin Williams10,11
11 affiliations
  1. 1Division of Adolescent and Young Adult Medicine, Mass General Brigham for Children, Boston
  2. 2Harvard Medical School, Boston, Massachusetts
  3. 3Department of Social and Behavioral Sciences, Yale University School of Public Health, New Haven, Connecticut
  4. 4Health Policy Research Center, Department of Medicine, Massachusetts General Hospital, Boston
  5. 5Independent researcher, Overland Park, Kansas
  6. 6Biostatistics Center, Massachusetts General Hospital, Boston
  7. 7Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles
  8. 8Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston
  9. 9Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
  10. 10Division on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, New York
  11. 11New York State Psychiatric Institute, New York
Open at sourceDOICite

Abstract

Importance: One in 100 adolescents and young adults (hereafter “youths”) in the US has an opioid use disorder (OUD), yet little is known about the extent to which they receive care aligned with national quality measures.

Objective: To evaluate progression through the OUD cascade of care (COC) among Medicaid-enrolled youths, with key stages of treatment aligned with national quality measures.

Design, Setting, and Participants: This cohort study used enrollment and health insurance claims from all US states and Washington, DC, from the 2016-2023 Transformed Medicaid Statistical Information System Analytic Files. Participants had OUD and were aged 13 to 25 years. Data were analyzed from November 3, 2025, to July 24, 2026.

Exposures: Diagnosis of OUD and receipt of addiction treatment, including behavioral health services and medications for OUD (MOUD; buprenorphine, methadone, or extended-release naltrexone).

Main Outcomes and Measures: Progression through COC stages aligned with national quality measures: treatment initiation, engagement, MOUD receipt, and 180-day MOUD retention.

Results: Among 229 847 youths with OUD enrolled in Medicaid (median age, 22 [IQR, 20-24] years; 117 920 females [51.3%]), 116 458 (50.7%) initiated treatment within 14 days of diagnosis, and 75 614 (32.9%) engaged in care (ie, had 2 or more additional treatment encounters within 34 days of treatment initiation). Among the 75 614 youths who engaged in treatment, 35 011 (46.3%) received MOUD, representing 15.2% of all 229 847 youths with OUD. However, only 554 of 8352 adolescents younger than 18 years who engaged in treatment received MOUD (6.6%), compared with 34 457 of 67 262 young adults 18 years and older (51.2%). Buprenorphine was the most initiated medication (n = 23 990 of 35 011 [68.5%]), followed by methadone (n = 8911 [25.5%]) and extended-release naltrexone (n = 2110 [6.0%]). Overall, only 7070 of 229 847 youths (3.1%) continued medication for 180 days or more. Among youths receiving MOUD, retention was highest for methadone (n = 2334 of 8911 [26.2%]), followed by buprenorphine (n = 4613 of 23 990 [19.2%]) and extended-release naltrexone (n = 123 of 2110 [5.8%]). Median time receiving MOUD varied by medication: methadone, 59 days (IQR, 15-189 days); buprenorphine, 45 days (IQR, 18-128 days); and extended-release naltrexone, 31 days (IQR, 28-82 days) (log-rank test, P < .001). Younger adolescents aged 13 to 15 years and racially minoritized youths had consistently lower progression through the COC.

Conclusions and Relevance: In this cohort study of Medicaid-enrolled youths with OUD, most did not receive timely, evidence-based treatment, and only 1 in 32 received sustained pharmacotherapy. Gaps and persistent disparities exist across the COC, particularly for youths of color, underscoring the need for policies and care models that expand equitable treatment access.

Related

  1. County-Level Context and Differential Policy Impacts on Buprenorphine Use Among Medicaid Enrollees with Opioid Use Disorder in Kentucky, 2018–2025
    Dustin K. Miracle, Svetla Slavova, Patricia R. Freeman +1
    Drug and alcohol dependencePeer-reviewedCC BYFull textEpidemiology & public healthPMC
  2. Prenatal Exposure to Wildfire PM2.5 and Risk of ASD and ADHD in Children Enrolled in Medicaid
    Stefania Papatheodorou, Hayon Michelle Choi, Krista F. Huybrechts +14
    JAMA PediatricsPeer-reviewedLicence not statedFull textObstetrics, gynaecology & paediatricsPMC
  3. Analysis of the costs and reach of transportation services to reduce barriers to opioid use disorder (OUD) treatment: evidence from the Kentucky HEALing Communities Study
    Drew D. Speer, Joshua L. Bush, Don Lochana Ekanayake +7
    Addiction Science & Clinical PracticePeer-reviewedCC BYFull text1 citedEpidemiology & public healthDOAJ
  4. Postpartum contraception receipt among Oregon Medicaid-funded births with stimulant and substance use disorder.
    Stephan R Lindner, Menolly Kaufman, Ann Martinez Acevedo +1
    Reproductive healthPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCDOAJ
  5. Preconception, Prenatal and Postnatal PM2.5 Exposure and Neurodevelopmental Disorder Risk among Medicaid Recipients.
    Matthew Shupler, Xinye Qiu, Krista F Huybrechts +12
    Environmental science & technologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{hadland2026opioid,
  title = {{Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths}},
  author = {Scott E. Hadland and Ijeoma Opara and Vicki Fung and Dandi Dong and Sitara Weerakoon and Jonathan Rodean and Marie-Abèle C. Bind and Bonnie T. Zima and Meredith Glass and Margarita Alegría and George Karandinos and Arthur Robin Williams},
  journal = {JAMA Network Open},
  year = {2026},
  month = oct,
  doi = {10.1001/jamanetworkopen.2026.37263},
  url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854760},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths
AU  - Scott E. Hadland
AU  - Ijeoma Opara
AU  - Vicki Fung
AU  - Dandi Dong
AU  - Sitara Weerakoon
AU  - Jonathan Rodean
AU  - Marie-Abèle C. Bind
AU  - Bonnie T. Zima
AU  - Meredith Glass
AU  - Margarita Alegría
AU  - George Karandinos
AU  - Arthur Robin Williams
PY  - 2026
DA  - 2026/10/02
JO  - JAMA Network Open
DO  - 10.1001/jamanetworkopen.2026.37263
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854760
AB  - Importance: One in 100 adolescents and young adults (hereafter “youths”) in the US has an opioid use disorder (OUD), yet little is known about the extent to which they receive care aligned with national quality measures.  Objective: To evaluate progression through the OUD cascade of care (COC) among Medicaid-enrolled youths, with key stages of treatment aligned with national quality measures.  Design, Setting, and Participants: This cohort study used enrollment and health insurance claims from all US states and Washington, DC, from the 2016-2023 Transformed Medicaid Statistical Information System Analytic Files. Participants had OUD and were aged 13 to 25 years. Data were analyzed from November 3, 2025, to July 24, 2026.  Exposures: Diagnosis of OUD and receipt of addiction treatment, including behavioral health services and medications for OUD (MOUD; buprenorphine, methadone, or extended-release naltrexone).  Main Outcomes and Measures: Progression through COC stages aligned with national quality measures: treatment initiation, engagement, MOUD receipt, and 180-day MOUD retention.  Results: Among 229 847 youths with OUD enrolled in Medicaid (median age, 22 [IQR, 20-24] years; 117 920 females [51.3%]), 116 458 (50.7%) initiated treatment within 14 days of diagnosis, and 75 614 (32.9%) engaged in care (ie, had 2 or more additional treatment encounters within 34 days of treatment initiation). Among the 75 614 youths who engaged in treatment, 35 011 (46.3%) received MOUD, representing 15.2% of all 229 847 youths with OUD. However, only 554 of 8352 adolescents younger than 18 years who engaged in treatment received MOUD (6.6%), compared with 34 457 of 67 262 young adults 18 years and older (51.2%). Buprenorphine was the most initiated medication (n = 23 990 of 35 011 [68.5%]), followed by methadone (n = 8911 [25.5%]) and extended-release naltrexone (n = 2110 [6.0%]). Overall, only 7070 of 229 847 youths (3.1%) continued medication for 180 days or more. Among youths receiving MOUD, retention was highest for methadone (n = 2334 of 8911 [26.2%]), followed by buprenorphine (n = 4613 of 23 990 [19.2%]) and extended-release naltrexone (n = 123 of 2110 [5.8%]). Median time receiving MOUD varied by medication: methadone, 59 days (IQR, 15-189 days); buprenorphine, 45 days (IQR, 18-128 days); and extended-release naltrexone, 31 days (IQR, 28-82 days) (log-rank test, P < .001). Younger adolescents aged 13 to 15 years and racially minoritized youths had consistently lower progression through the COC.  Conclusions and Relevance: In this cohort study of Medicaid-enrolled youths with OUD, most did not receive timely, evidence-based treatment, and only 1 in 32 received sustained pharmacotherapy. Gaps and persistent disparities exist across the COC, particularly for youths of color, underscoring the need for policies and care models that expand equitable treatment access.
SN  - 2574-3805
ER  -